ザ・ベーシックメソッド　心不全　薬物治療

出版社： メジカルビュー社
著者：
発行日： 2021-03-31
分野： 臨床医学：内科  >  循環器一般
ISBN： 9784758319683
電子書籍版： 2021-03-31 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

6,600 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

6,600 円(税込)

購入する

商品紹介

病態が複雑で治療薬の種類が多く，適切な投与が難しい心不全の薬物治療を，第一線の執筆陣が実体験を基に詳細に解説。基礎知識と実践のLINK機能により，身に付けた基礎知識を実践で的確に使いこなすことができる構成。また，エビデンスだけでは解決できない実臨床における「投与の勘ドコロ」を，フローチャートやイラストなど豊富な図表を駆使してビジュアルで理解でき，既存薬はもちろん，新規治療薬（イバブラジン，サクビトリルバルサルタン，SGLT2阻害薬）の実践的な使い方・活かし方，服薬管理・ポリファーマシー対策までを網羅。心不全の薬物治療を自信をもって行うための新たな定番書が誕生！

目次

  • I章 【掟】 心不全薬物治療のオキテ−まずはこれだけ
    　1. 急性期
    　2. 慢性期
    　3. HFrEF
    　4. HFpEF
    　5. HFmrEF
    　　
    II章 【基礎知識】 心不全治療薬を使いこなすために
    　1. ACE阻害薬
    　2. ARB
    　3. β遮断薬
    　4. 強心薬〔静注〕
    　5. 強心薬〔経口〕
    　6. 血管拡張薬〔静注〕
    　7. 血管拡張薬〔経口〕
    　8. 利尿薬〔静注〕
    　9. 利尿薬〔経口〕
    　10. 抗不整脈薬〔静注〕　
    　11. 抗不整脈薬〔経口〕
    　12. 抗凝固薬
    　13. 麻薬・鎮静薬
    　14. SGLT2阻害薬
    　15. Ifチャネル阻害薬
    　16. ARNI
    　17. sGC刺激薬
    　18. 心筋ミオシン活性化薬
    　19. 服薬管理
    　20. ポリファーマシー対策

    III章 【実践】 基礎疾患・併存症への薬物治療
    (1)基礎疾患
    　1. 急性冠症候群
    　2. 急性心筋炎
    　3. 虚血性心疾患
    　4. 高血圧性心疾患
    　5. 拡張型心筋症
    　6. 肥大型心筋症
    　7. 心臓アミロイドーシス　
    　8. ファブリー病
    　9. 弁膜症
    　10. 心房細動
    　11. 肺高血圧症（第2群肺高血圧症）
    　12. 成人先天性心疾患
    　13. 収縮性心膜炎

    (2)併存症
    　1. 糖尿病
    　2. 慢性腎臓病（CKD）
    　3. 高尿酸血症　
    　4. 慢性閉塞性肺疾患
    　5. 貧血
    　6. 電解質異常

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I章 掟 Rules 心不全薬物治療のオキテ - まずはこれだけ

P.5 掲載の参考文献
1) 日本循環器学会/日本心不全学会:急性・慢性心不全診療ガイドライン(2017年改訂版). 2018. https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf
 
2) Levy B, Clere-Jehl R, Legras A, et al:Epinephrine Versus Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction. J Am Coll Cardiol 72:173-182, 2018.
PubMed
3) Cotter G, Metzkor E, Kaluski E, et al:Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 351:389-393, 1998.
PubMed
4) Stevenson LW, Perloff JK:The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 261:884-888, 1989.
PubMed
5) Lam CSP, Li YH, Bayes-Genis A, Ariyachaipanich A, et al:The role of N-terminal pro-B-type natriuretic peptide in prognostic evaluation of heart failure. J Chin Med Assoc 82:447-451, 2019.
 
6) Cooper LB, DeVore AD, Felker GM:The Impact of Worsening Heart Failure in the United States. Heart Fail Clin 11:603-614, 2015.
 
7) Kajimoto K, Sato N, Takano T:Relationship of renal insufficiency and clinical features or comorbidities with clinical outcome in patients hospitalised for acute heart failure syndromes. Eur Heart J Acute Cardiovasc Care 6:697-708, 2017.
PubMed
P.12 掲載の参考文献
1) 日本循環器学会/日本心不全学会:急性・慢性心不全診療ガイドライン(2017年改訂版). 2018. https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf
 
2) McMurray JJV, Solomon SD, Inzucchi SE, et al:Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 381:1995-2008, 2019.
PubMed
3) Packer M, Anker SD, Butler J, et al:Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 383:1413-1424, 2020.
PubMed
4) Swedberg K, Komajda M, Bohm M, et al:Ivabradine and outcomes in chronic heart failure (SHIFT):a randomised placebo-controlled study. Lancet 376:875-885, 2010.
PubMed
5) McMurray JJV, Packer M, Desai AS, et al:Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993-1004, 2014.
PubMed
P.18 掲載の参考文献
1) McMurray JJV, Packer M, Desai AS, et al:Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993-1004, 2014.
PubMed
2) Swedberg K, Komajda M, Bohm M, et al:Ivabradine and outcomes in chronic heart failure (SHIFT):a randomised placebo-controlled study. Lancet 376:875-885, 2010.
PubMed
3) McMurray JJV, Solomon SD, Inzucchi SE, et al:Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 381:1995-2008, 2019.
PubMed
4) Packer M, Anker SD, Butler J, et al:Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med 383:1413-1424, 2020.
PubMed
5) Ponikowski P, Voors AA, Anker SD, et al:2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18:891-975, 2016.
 
P.25 掲載の参考文献
1) Lund LH, Claggett B, Liu J, et al:Heart failure with mid-range ejection fraction in CHARM:characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail 20:1230-1239, 2018.
PubMed
2) Fukuta H, Goto T, Wakami K, et al:Effect of renin-angiotensin system inhibitors on mortality in heart failure with preserved ejection fraction:a meta-analysis of observational cohort and randomized controlled studies. Heart Fail Rev 22:775-782, 2017.
PubMed
3) Fukuta H, Goto T, Wakami K, et al:The effect of beta-blockers on mortality in heart failure with preserved ejection fraction:A meta-analysis of observational cohort and randomized controlled studies. Int J Cardiol 228:4-10, 2017.
PubMed
4) Solomon SD, Claggett B, Lewis EF, et al:Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 37:455-462, 2016.
PubMed
5) Solomon SD, McMurray JJV, Anand IS, et al:Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med 381:1609-1620, 2019.
PubMed
P.30 掲載の参考文献
1) Totzeck M, Schuler M, Stuschke M, et al:Cardio-oncology-strategies for management of cancer-therapy related cardiovascular disease. Int J Cardiol 280:163-175, 2019.
PubMed
2) Lund LH, Claggett B, Liu J, et al:Heart failure with mid-range ejection fraction in CHARM:characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail 20:1230-1239, 2018.
PubMed
3) Solomon SD, Claggett B, Lewis EF, et al:Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 37:455-462, 2016.
PubMed
4) Solomon SD, McMurray JJV, Anand IS, et al:Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med 381:1609-1620, 2019.
PubMed
5) Cleland JGF, Bunting KV, Flather MD, et al:Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction:an individual patient-level analysis of double-blind randomized trials. Eur Heart J 39:26-35, 2018.
PubMed
6) Yamamoto K, Origasa H, Hori M:Effects of carvedilol on heart failure with preserved ejection fraction:the Japanese Diastolic Heart Failure Study(J-DHF). Eur J Heart Fail 15:110-118, 2013.
PubMed
7) Masuyama T, Tsujino T, Origasa H, et al:Superiority of long-acting to short-acting loop diuretics in the treatment of congestive heart failure. Circ J 76:833-842, 2012.
PubMed

II章 基礎知識 Knowledge 心不全治療薬を使いこなすために

P.39 掲載の参考文献
1) 日本循環器学会/日本心不全学会:急性・慢性心不全診療ガイドライン(2017年改訂版). 2018. https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf
 
2) Yoshimura M, Kawai M:Synergistic inhibitory effect of angiotensin II receptor blocker and thiazide diuretic on the tissue renin-angiotensin-aldosterone system. J Renin Angiotensin Aldosterone Syst 11:124-126, 2010.
PubMed
3) Mizuno Y, Yoshimura M, Yasue H, et al:Aldosterone production is activated in failing ventricle in humans. Circulation 103:72-77, 2001.
PubMed
4) Mukoyama M, Nakao K, Hosoda K, et al:Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide:J Clin Invest 87:1402-1412, 1991.
PubMed
5) Suzuki S, Yoshimura M, Nakayama M, et al:Plasma level of B-type natriuretic peptide as a prognostic marker after acute myocardial infarction:a long-term follow-up analysis. Circulation 110:1387-1391, 2004.
PubMed
P.45 掲載の参考文献
1) Yancy CW, Jessup M, Bozkurt B, et al:2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 136:e137-e161, 2017.
 
2) Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators:A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345:1667-1675, 2001.
 
3) McMurray JJV, Ostergren J, Swedberg K, et al:Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors:the CHARM-Added trial. Lancet 362:767-771, 2003.
PubMed
4) Yusuf S, Pfeffer MA, Swedberg K, et al:Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction:the CHARM-Preserved Trial. Lancet 362:777-781, 2003.
PubMed
5) Steckelings UM, Widdop RE, Paulis L, Unger T:The angiotensin AT2 receptor in left ventricular hypertrophy. J Hypertens 28 (Suppl 1):S50-S55, 2010.
 
6) Pfeffer MA, McMurray JJV, Velazquez EJ, et al:Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349:1893-1906, 2003.
 
7) Pitt B, Poole-Wilson PA, Segal R, et al:Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure:randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 355:1582-1587, 2000.
PubMed
8) Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators:A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 345:1667-1675, 2001.
 
9) Granger CB, McMurray JJV, Yusuf S, et al:Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors:the CHARM-Alternative trial. Lancet 362:772-776, 2003.
PubMed
10) Heran BS, Musini VM, Bassett K, et al:Angiotensin receptor blockers for heart failure. Cochrane Database Syst Rev 2012:CD003040, 2012.
PubMed
11) Burnett H, Earley A, Voors AA, et al:Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction:A Network Meta-Analysis. Circ Heart Fail 10:e003529, 2017.
PubMed
12) Matsuzaki M, Yamamoto K, Yano M, et al:Efficacy and safety of a 60-week treatment with candesartan in Japanese patients with mild to moderate chronic heart failure. J Cardiol 61(4):267-274, 2013.
PubMed
13) Matsumori A, Assessment of Response to Candesartan in Heart Failure in Japan (ARCH-J) Study Investigators:Efficacy and safety of oral candesartan cilexetil in patients with congestive heart failure. Eur J Heart Fail 5:669-677, 2003.
 
14) Konstam MA, Neaton JD, Dickstein K, et al:Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study):a randomised, double-blind trial. Lancet 374:1840-1848, 2009.
PubMed
P.52 掲載の参考文献
1) 日本循環器学会/日本心不全学会:急性・慢性心不全診療ガイドライン(2017年改定版). 2018.https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf
 
2) Hori M, Sasayama S, Kitabatake A, et al:Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure:The Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 147:324-330, 2004.
PubMed
3) Cullington D, Goode KM, Clark AL, Cleland JGF:Heart rate achieved or beta-blocker dose in patients with chronic heart failure:which is the better target? Eur J Heart Fail 14:737-747, 2012.
PubMed
4) Kotecha D, Holmes J, Krum H, et al:Efficacy of β blockers in patients with heart failure plus atrial fibrillation:an individual-patient data meta-analysis. Lancet 384:2235-2243, 2014.
 
5) Yamamoto K, Origasa H, Hori M, J-DHF Investigators:Effects of carvedilol on heart failure with preserved ejection fraction:the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail 15(1):110-118, 2013.
PubMed
6) Nagai R, Kinugawa K, Inoue H, et al:Urgent Management of Rapid Heart Rate in Patients With Atrial Fibrillation/Flutter and Left Ventricular Dysfunction-Comparison of the Ultra-Short-Acting β1-Selective Blocker Landiolol With Digoxin (J-Land Study) -. Circ J 77:908-916, 2013.
 
7) Prins KW, Neill JM, Tyler JO, et al:Effects of Beta-Blocker Withdrawal in Acute Decompensated Heart Failure:A Systematic Review and Meta-Analysis. JACC Heart Failure 3:647-653, 2015.
PubMed
P.57 掲載の参考文献
1) 日本循環器学会/日本心不全学会:急性・慢性心不全診療ガイドライン(2017年改訂版). 2018. https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf
 
2) Mebazaa A, Parissis J, Porcher R, et al:Short-term survival by treatment among patients hospitalized with acute heart failure:the global ALARM-HF registry using propensity scoring methods. Intensive Care Med 37:290-301, 2011.
PubMed
3) Tacon CL, McCaffrey J, Delaney A:Dobutamine for patients with severe heart failure:a systematic review and meta-analysis of randomised controlled trials. Intensive Care Med 38:359-367, 2012.
PubMed
4) De Backer D, Biston P, Devriendt J, et al:Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 362:779-789, 2010.
 
5) Cuffe MS, Califf RM, Adams KF Jr, et al:Short-term intravenous milrinone for acuteexacerbation of chronic heart failure:a randomized controlled trial. JAMA 287:1541-1547, 2002.
 
P.63 掲載の参考文献
1) 日本循環器学会/日本心不全学会:急性・慢性心不全診療ガイドライン(2017年改定版). 2018. https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf
 
2) Lubsen J, Just H, Hjalmarsson AC, et al:Effect of pimobendane on exercise capacity in patients with heart failure:main results from the Pimobendan in Congestive Heart Failure(PICO) trial. Heart 76:223-231, 1996.
PubMed
3) EPOCH Study Group:Effects of pomobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure:the effects of pimobendane on chronic heart failure study (EPOCH study). Circ J 66:149-157, 2002.
 
4) Digitalis Investigation Group:The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336:525-533, 1997.
 
P.70 掲載の参考文献
1) 日本循環器学会/日本心不全学会:急性・慢性心不全診療ガイドライン(2017年改訂版). 2018. https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf
 
2) Abraham WT, Adams KF, Fonarow GC, et al:In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications:an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 46:57-64, 2005.
 
3) O'Connor CM, Starling RC, Hernandez AF, et al:Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 365:32-43, 2011.
 
4) Packer M, O'Connor C, McMurray JJV, et al:Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure. N Engl J Med 376:1956-1964, 2017.
PubMed
5) Metra M, Teerlink JR, Cotter G, et al:Effects of Serelaxin in Patients with Acute Heart Failure. N Engl J Med 381:716-726, 2019.
PubMed
6) Hata N, Seino Y, Tsutamoto T, et al:Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure:the PROTECT multicenter randomized controlled study. Circ J 72:1787-1793, 2008.
 
7) Kitakaze M, Asakura M, Kim J, et al:Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND):two randomised trials. Lancet 370:1483-1493, 2007.
PubMed
8) Sezai A, Hata M, Niino T, et al:Continuous low-dose infusion of human atrial natriuretic peptide in patients with left ventricular dysfunction undergoing coronary artery bypass grafting:the NU-HIT (Nihon University working group study of low-dose Human ANP Infusion Therapy during cardiac surgery) for left ventricular dysfunction. J Am Coll Cardiol 55:1844-1851, 2010.
 
9) Kozhuharov N, Goudev A, Flores D, et al:Effect of a Strategy of Comprehensive Vasodilation vs Usual Care on Mortality and Heart Failure Rehospitalization Among Patients With Acute Heart Failure:The GALACTIC Randomized Clinical Trial. JAMA 322:2292-2302, 2019.
PubMed
10) Curfman G:Vasodilator Therapy in Acute Heart Failure. JAMA 322:2288-2289, 2019
PubMed
P.78 掲載の参考文献
1) 日本高血圧学会:高血圧治療ガイドライン2019. ライフサイエンス出版, 東京, 2019.
 
2) 日本循環器学会/日本心不全学会:急性・慢性心不全診療ガイドライン(2017年度改定版). 2018. https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf
 
3) van der Meer P, Gaggin HK, Dec GW:ACC/AHA Versus ESC Guidelines on Heart Failure:JACC Guideline Comparison. J Am Coll Cardiol 73:2756-2768, 2019.
PubMed
4) ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group:Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic:The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288:2981-2997, 2002.
PubMed
5) Brown MJ, Palmer CR, Castaigne A, et al:Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study:Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 356:366-372, 2000.
PubMed
6) Hansson L, Hedner T, Lund-Johansen P, et al:Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension:the Nordic Diltiazem (NORDIL) study. Lancet 356:359-365, 2000.
PubMed
7) Lim SL, Benson L, Dahlstrom U, et al:Association Between Use of Long-Acting Nitrates and Outcomes in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail 10:e003534, 2017.
PubMed
8) Redfield MM, Anstrom KJ, Levine JA, et al:Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. N Engl J Med 373:2314-2324, 2015.
PubMed
9) Redfield MM, Chen HH, Borlaug BA, et al:RELAX Trial. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction:a randomized clinical trial. JAMA 309:1268-1277, 2013.
PubMed
10) Hoendermis ES, Liu LCY, Hummel YM, et al:Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension:a randomized controlled trial. Eur Heart J 36:2565-2573, 2015.
PubMed
11) Liu LCY, Hummel YM, van der Meer P, et al:Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health-related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension. Eur J Heart Fail 19:116-125, 2017.
 
P.84 掲載の参考文献
1) 日本循環器学会/日本心不全学会:急性・慢性心不全診療ガイドライン(2017年改訂版). 2018. https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf
 
2) Yancy CW, Jessup M, Bozkurt B, et al:2013 ACCF/AHA guideline for the management of heart failure:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62:e147-e239, 2013.
 
3) Ponikowski P, Voors AA, Anker SD, et al:2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37:2129-2200, 2016.
 
4) Felker GM, Lee KL, Bull DA, et al:Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 364:797-805, 2011.
PubMed
5) Matsue Y, Damman K, Voors AA, et al:Time-to-Furosemide Treatment and Mortality in Patients Hospitalized With Acute Heart Failure. J Am Coll Cardiol 69:3042-3051, 2017.
PubMed
6) Hollenberg SM, Stevenson LW, Ahmad T, et al:2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With Heart Failure:A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 74:1966-2011, 2019.
 
P.92 掲載の参考文献
1) 日本循環器学会/日本心不全学会:急性・慢性心不全診療ガイドライン(2017年改訂版). 2018. https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf
 
2) Masuyama T, Tsujino T, Hideki Origasa H, et al:Superiority of long-acting to short-acting loop diuretics in the treatment of congestive heart failure. Circ J 76:833-842, 2012.
 
3) Pitt B, Zannad F, Remme WJ, et al:The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709-717, 1999.
 
4) Zannad F, McMurray JJV, Krum H, et al:Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364:11-21, 2011.
PubMed
5) Konstam MA, Gheorghiade M, Burnett JC Jr, et al:Effects of oral tolvaptan in patients hospitalized for worsening heart failure:the EVEREST Outcome Trial. JAMA 297:1319-1331, 2007.
PubMed
P.98 掲載の参考文献
1) 日本循環器学会/日本不整脈心電学会:2020年改訂版 不整脈薬物治療ガイドライン. 2020. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/01/JCS2020_Ono.pdf
 
2) The antiarrhythmics versus implantable defibrillators (AVID) investigators:A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 337:1576-1583, 1997.
 
3) Kundenchuk PJ, Brown SP, Daya M, et al:Amiodrone, Lidocaine, or Place in out-of-hospital cardiac arrest. N Engl J Med 374:1711-1722, 2016.
 
P.104 掲載の参考文献
1) 日本循環器学会/日本不整脈心電学会:2020年改訂版 不整脈の薬物治療ガイドライン. 2020. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/01/JCS2020_Ono.pdf
 
2) 日本循環器学会/日本不整脈心電学会:不整脈非薬物治療ガイドライン(2018年改訂版). 2019. https://www.j-circ.or.jp/old/guideline/pdf/JCS2018_kurita_nogami.pdf
 
3) Vaughan Wiliams EM:Classification of antiarrhythmic drugs (Snadoe E, Flensted-Jensen E, Olsen KH, ed). Symposium on cardiac arrhythmias, Sweden, Astra, 1970, p449-472.
 
4) Cardiac Arrhythmia Suppression Trial (CAST) Investigators:Preliminary report:effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321:406-412, 1989.
 
5) Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators:A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 337(22):1576-1583, 1997.
 
6) Connolly SJ, Hallstrom AO, Cappato R, et al:Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. Eur Heart J 21:2071-2078, 2000.
 
P.111 掲載の参考文献
1) 日本循環器学会/日本心不全学会:急性・慢性心不全ガイドライン(2017年改訂版). 2018. https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf
 
2) 日本循環器学会, 日本冠疾患学会ほか:2020年JCSガイドライン フォーカスアップデート版 冠動脈疾患患者における抗血栓療法. 2020. https://www.j-circ.or.jp/old/guideline/pdf/JCS2020_Kimura_Nakamura.pdf
 
3) Savarese G, Giugliano RP, Rosano GM, et al:Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure:A Meta-Analysis. JACC Heart Fail 4:870-880, 2016.
PubMed
4) Robinson AA, Trankle CR, Eubanks G, et al:Off-label Use of Direct Oral Anticoagulants Compared With Warfarin for Left Ventricular Thrombi. JAMA Cardiol 5:685-692, 2020.
PubMed
5) Yasuda S, Kaikita K, Akao M, et al:Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. N Engl J Med 381:1103-1113, 2019.
PubMed
6) Maniwa N, Fujino M, Yasuda S, et al:Anticoagulation combined with antiplatelet therapy in patients with left ventricular thrombus after first acute myocardial infarction. Eur Heart J 39:201-208, 2018.
PubMed
P.118 掲載の参考文献
1) Vismara LA, Leaman DM, Zelis R:The effects of morphine on venous tone in patients with acute pulmonary edema. Circulation 54:335-337, 1976.
PubMed
2) 日本緩和医療学会ガイドライン統括委員会編:2018年版 がん患者の治療抵抗性の苦痛と鎮静に関する基本的な考え方の手引き. 金原出版, 東京, 2018.
 
3) 大石醒悟:麻薬, 鎮静薬の考え方, 使い方と倫理的判断. 心不全治療薬の考え方, 使い方. 中外医学社, 2019.
 
4) 大石醒悟:身体的苦痛への対応. 心不全の緩和ケア 改訂2版. 南山堂, 東京, 2020.
 
5) 日本循環器学会/日本心不全学会:急性・慢性心不全診療ガイドライン(2017年改訂版). 2018. https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf
 
6) Hamatani Y, Anzai T, Izumi C, et al:Survey of Palliative Sedation at End of Life in Terminally Ill Heart Failure Patients-A Single-Center Experience of 5-Year Follow-up. Circ J 83:1607-1611, 2019.
PubMed
7) 日本医師会監修:新版 がん緩和ケアガイドブック. 青海社, 東京, 2017.
 
8) Twycross Rほか:トワイクロス先生のがん緩和ケア処方薬(武田文和ほか監訳). 医学書院, 東京, 2013.
 
P.124 掲載の参考文献
1) American Diabetes Association:Cardiovascular Disease and Risk Management:Diabetes Care 43 (Suppl 1):S111-S134, 2020.
PubMed
2) Cosentino F, Grant PJ, Aboyans V, et al;ESC Scientific Document Group:2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 41:255-323, 2020.
 
3) Verma S, Rawat S, Ho KL, et al:Empagliflozin Increases Cardiac Energy Production in Diabetes:Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors. JACC Basic Transl Sci 3:575-587, 2018.
PubMed
4) Verma S, McMurray JJV:SGLT2 inhibitors and mechanisms of cardiovascular benefit:a state-of-the-art review. Diabetologia 61:2108-2117, 2018.
PubMed
5) 日本循環器学会/日本心不全学会:急性・慢性心不全診療ガイドライン(2017年改訂版). 2018. https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf
 
6) McMurray JJV, Solomon SD, Inzucchi SE, et al;DAPA-HF Trial Committees and Investigators:Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 381:1995-200, 2019.
PubMed
7) Packer M, Anker SD, Butler J, et al;EMPEROR-Reduced Trial Investigators:Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383:1413-1424, 2020.
PubMed
8) Bhatt DL, Szarek M, Steg PG, et al;SOLOIST-WHF Trial Investigators:Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med 384:117-128, 2021.
PubMed
9) McMurray JJV, Packer M:How Should We Sequence the Treatments for Heart Failure and a Reduced Ejection Fraction? A Redefinition of Evidence-Based Medicine. Circulation 2020 [Epub ahead of print].
 
10) Heerspink HJL, Stefansson BV, Correa-Rotter R, et al;DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med 383(15):1436-1446, 2020.
PubMed
11) Bhatt DL, Szarek M, Pitt B et al;SCORED Investigators:Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med 2020[Epub ahead of print].
 
12) Das SR, Everett BM, Birtcher KK et al:2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes:A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 76:1117-1145, 2020.
 
P.131 掲載の参考文献
1) Gillman MW, Kannel WB, Belanger A, D'Agostino RB:Influence of heart rate on mortality among persons with hypertension:the Framingham Study. Am Heart J 125:1148-1154, 1993.
PubMed
2) Fox K, Ford I, Steg PG, et al:BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL):a randomised, double-blind, placebo-controlled trial. Lancet 372:807-816, 2008.
PubMed
3) Swedberg K, Komajda M, Bohm M, et al:Ivabradine and outcomes in chronic heart failure (SHIFT):a randomised placebo-controlled study. Lancet 376:875-885, 2010.
PubMed
4) Tsutsui H, Momomura S, Yamashina A, et al:Efficacy and Safety of Ivabradine in Japanese Patients With Chronic Heart Failure-J-SHIFT Study. Circ J 83:2049-2060, 2019.
PubMed
5) Komajda M, Isnard R, Cohen-Solal A, et al:Effect of ivabradine in patients with heart failure with preserved ejection fraction:the EDIFY randomized placebo-controlled trial. Eur J Heart Fail 19:1495-1503, 2017.
 
6) Volterrani M, Cice G, Caminiti G, et al:Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial). Int J Cardiol 151:218-224, 2011.
PubMed
P.137 掲載の参考文献
1) Seferovic PM, Ponikowski P, Anker SD, et al:Clinical practice update on heart failure 2019:pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 21:1169-1186, 2019.
 
2) McMurray JJV, Packer M, Desai AS, et al:PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371:993-1004, 2014.
PubMed
3) Solomon SD, McMurray JJV, Anand IS, et al:Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med 381:1609-1620, 2019.
PubMed
4) Myhre PL, Vaduganathan M, Claggett B, et al:B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan:The PARADIGM-HF Trial. J Am Coll Cardiol 73:1264-1272, 2019.
 
5) Vodovar N, Paquet C, Mebazaa A, et al:Neprilysin, cardiovascular, and Alzheimer's diseases:the therapeutic split? Eur Heart J 36:902-905, 2015.
PubMed
P.145 掲載の参考文献
1) Greene SJ, Gheorghiade Borlaug BA, et al:The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction. J Am Heart Assoc 2:e000536, 2013.
PubMed
2) Van Heerebeek L, Hamdani N, Falcao-Pires I, et al:Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation 126, 830-839, 2012.
PubMed
3) Armstrong PW, Pieske B, Anstrom KJ, et al:Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 382:1883-1893, 2020.
PubMed
4) Paulus WJ, Tschope C:A Novel Paradigm for Heart Failure With Preserved Ejection Fraction Comorbidities Drive Myocardial Dysfunction and Remodeling Through Coronary Microvascular Endothelial Inflammation. J Am Coll Cardiol 62:263-271, 2013.
PubMed
5) Takimoto E, Koitabashi N, Hsu S, et al:Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. J Clin Invest 119:408-420, 2009.
PubMed
6) Layland J, Solaro RJ, Shah AM:Regulation of cardiac contractile function by troponin I phosphorylation. Cardiovasc Res 66:12-21, 2005.
PubMed
7) Wijnker PJM, Murphy AM, Stienen GJM, van der Velden J:Troponin I phosphorylation in human myocardium in health and disease. Neth Heart J 22:463-469, 2014.
PubMed
8) Copeland ON, Sadayappan S, Messer AE, et al:Analysis of cardiac myosin binding protein-C phosphorylation in human heart muscle. J Mol Cell Cardiol 49:1003-1011, 2010.
PubMed
9) Sadayappan S, Gulick J, Osinska H, et al:Cardiac myosin-binding protein-C phosphorylation and cardiac function. Circ Res 97:1156-1163, 2005.
PubMed
10) Kensler RW, Craig R, Moss RL:Phosphorylation of cardiac myosin binding protein C releases myosin heads from the surface of cardiac thick filaments. Proc Natl Acad Sci USA 114:E1355-E1364, 2017.
 
11) Thoonen R, Giovanni S, Govindan S:Molecular Screen Identifies Cardiac Myosin-Binding Protein-C as a Protein Kinase G-Iα Substrate. Circ Heart Fail 8:1115-1122, 2015.
 
12) Wang H, Kohr MJ, Traynham CJ, Ziolo MT:Phosphodiesterase 5 restricts NOS3/Soluble guanylate cyclase signaling to L-type Ca2+ current in cardiac myocytes. J Mol Cell Cardiol 47:304-314, 2009.
 
13) Koitabashi N, Aiba T, Hesketh GG, et al:Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation:Novel mechanism of cardiac stress modulation by PDE5 inhibition. J Mol Cell Cardiol 48:713-724, 2010.
 
14) Yao X:TRPC, cGMP-dependent protein kinases and cytosolic Ca2+. Handb Exp Pharmacol:527-540, 2007.
PubMed
15) Mattiazzi A, Mundina-Weilenmann C, Guoxiang C, et al:Role of phospholamban phosphorylation on Thr17 in cardiac physiological and pathological conditions. Cardiovasc Res 68:366-375, 2005.
 
16) Hua ZY, Zhang MH, Sears CE, et al:Reduced Phospholamban Phosphorylation Is Associated With Impaired Relaxation in Left Ventricular Myocytes From Neuronal NO Synthase-Deficient Mice. Circ Res 102:242-249, 2008.
 
17) Linke WA, Hamdani N:Gigantic business:Titin properties and function through thick and thin. Circ Res 114:1052-1068, 2014.
PubMed
18) Ranek MJ, Terpstra EJM, Li J, et al:Protein Kinase G Positively Regulates Proteasome-Mediated Degradation of Misfolded Proteins. Circulation 128:365-376, 2013.
 
19) Ranek MJ, Kokkonen-Simon KM, Chen A, et al:PKG1-modified TSC2 regulates mTORC1 activity to counter adverse cardiac stress. Nature 566:264-269, 2019.
 
20) Koka S, Kukreja RC:Attenuation of Doxorubicin-induced Cardiotoxicity by Tadalafil:A Long Acting Phosphodiesterase-5 Inhibitor. Mol Cell Pharmacol 2:173-178, 2010.
PubMed
21) Krishnan SM, Kraehling JR, Eitner F, et al:The impact of the nitric oxide(no)/soluble guanylyl cyclase(sGC)signaling cascade on kidney health and disease:A preclinical perspective. Int J Mol Sci 19:1712, 2018.
 
22) Sasaki H, Nagayama T, Blanton, RM, et al:PDE5 inhibitor efficacy is estrogen dependent in female heart disease. J Clin Invest 124:2464-2471, 2014.
 
23) Gheorghiade M, Greene SJ, Butler J, et al:Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients withworsening chronic heart failure and reduced ejection fraction the socrates-reduced randomized trial. JAMA 314:2251-2262, 2015.
 
24) Pieske P, Maggioni AP, Lam CSP, et al:Vericiguat in patients withworsening chronic heart failure and preserved ejection fraction:results of the SOluble guanylateCyclase stimulatoR in heArT failurE patientS with PRESERVEDEF(SOCRATES-PRESERVED)study. Eur Heart J 38:1119-1127, 2017.
 
25) Udelson JE, Lewis GD, Shah SJ, et al:Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients with Heart Failure with Preserved Ejection Fraction:The CAPACITY HFpEF Randomized Clinical Trial. JAMA 324:1522-1531, 2020.
 
26) Armstrong PW, Lam CSP, Anstrom KJ, et al:Effect of Vericiguat vs Placebo on Quality of Life in Patients with Heart Failure and Preserved Ejection Fraction:The VITALITY-HFpEF Randomized Clinical Trial. JAMA 324, 1512-1521:2020.
 
27) Mishra S, Kass DA:Cellular and molecular pathobiology of heart failure with preserved ejection fraction. Nat Rev Cardiol 2021[Online ahead of print]
 
P.151 掲載の参考文献
1) Packer M, Carver JR, Rodeheffer RJ, et al:Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 325:1468-1475, 1991.
 
2) Hampton JR, van Veldhuisen DJ, Kleber FX, et al:Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIMEII) Investigators. Lancet 349:971-977, 1997.
 
3) Cohn JN, Goldstein SO, Greenberg BH, et al:A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med 339:1810-1816, 1998.
 
4) Malik FI, Hartman JJ, Elias KA, et al:Cardiac myosin activation:a potential therapeutic approach for systolic heart failure. Science 331:1439-1443, 2011.
PubMed
5) Teerlink JR, Clarke CP, Saikali KG, et al:Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil:a first-in-man study. Lancet 378:667-675, 2011.
 
6) Cleland JG, Teerlink JR, Senior R, et al:The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure:a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet 378:676-683, 2011.
PubMed
7) Teerlink JR, Felker GM, McMurray JJ, et al:Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure:The ATOMIC-AHF Study. J Am Coll Cardiol 67:1444-1455, 2016.
 
8) Teerlink JR, Felker GM, McMurray JJ, et al:Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF):a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet 388:2895-2903, 2016.
PubMed
9) Teerlink JR, Diaz R, Felker GM, et al:Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. N Engl J Med 2020[Online ahead of print].
 
10) Teerlink JR, Diaz R, Felker GM, et al:Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction:GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials. Eur J Heart Fail 22:2160-2171, 2020.
PubMed
11) McMurray JJ, Packer M, Desai AS, et al:Angiotensin-neprilysin inhibition versus enalapril in heart failure. PARADIGM-HF Investigators and Committees. N Engl J Med 371:993-1004, 2014.
PubMed
12) McMurray JJV, Solomon SD, Inzucchi SE, et al:Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995-2008, 2019.
PubMed
13) Armstrong PW, Pieske B, Anstrom KJ, et al:Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 382:1883-1893, 2020.
PubMed
P.158 掲載の参考文献
1) 林 亜希子, 岡田明子, 眞茅みゆき:心不全患者の服薬行動に関する研究の動向と課題-Systematic Reviewからの考察. 心臓 50:152-163, 2018.
Medical*Online
2) Sabate E:Adherence to long-term therapies:Evidence for action. World Health Organization, Geneva, 2003.
 
3) Morisky DE, Ang A, Krousel-Wood M, Ward HJ:Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens (Greenwich) 10:348-354, 2008.
 
4) Bosworth HB, Granger BB, Mendys P, et al:Medication adherence:A call for action. Am Heart J 162:412-424, 2011.
 
5) Ruppar TM, Cooper PS, Mehr DR, et al:Medication adherence interventions improve heart failure mortality and readmission rates:Systematic review and meta-analysis of controlled trials. J Am Heart Assoc 5:e002606, 2016.
PubMed
6) Parajuli DR, Kourbelis C, Franzon J, et al:Effectiveness of the pharmacist-involved multidisciplinary management of heart failure to improve hospitalizations and mortality rates in 4630 patients:A systematic review and meta-analysis of randomized controlled trials. J Card Fail 25:744-756, 2019.
PubMed
P.163 掲載の参考文献
1) 日本老年医学会/日本医療研究開発機構研究費「高齢者の薬物治療の安全性に関する研究」研究班編:高齢者の安全な薬物療法ガイドライン2015. 日本老年医学会, 東京, 2015.
 
2) 厚生労働省:高齢者の医薬品適正使用の指針(総論編). 2018年5月. https://www.mhlw.go.jp/content/11121000/koureitekisei_web.pdf
 

III章 実践 Practice 基礎疾患・併存症への薬物治療

P.178 掲載の参考文献
1) Fiedler A:Ueber acute interstitielle Myokarditis. Festschrift zur Feier des 50 Jahr. Bestehens des Stadtkrankenheuses Dresden-Friedrichstadt. Dresden part 2, 1899, p3.
 
2) McCarthy RE 3rd, Boehmer JP, Hruban RH, et al:Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 342:690-695, 2000.
PubMed
3) 日本循環器学会ほか:循環器病の診断と治療に関するガイドライン(2008年度合同研究班報告):急性および慢性心筋炎の診断・治療に関するガイドライン(2009年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2009_izumi_h.pdf
 
4) Naruke T, Inomata T, Imai H, et al:End-tidal Carbon Dioxide Concentration Can Determine the Appropriate Recommendation to Wean Off Extracorporeal Membrane Oxygenation for Refractory Circulatory Failure. Int Heart J 51:116-120, 2010.
 
5) Mason JW, O'Connell JB, Herskowitz A, et al:A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 333:269-275, 1995.
 
6) Cooper LT Jr, Berry GJ, Shabetai R:Idiopathic giant-cell myocarditis. Natural history and treatment. N Engl J Med 336:1860-1866, 1997.
PubMed
7) Kato S, Morimoto S, Hiramitsu S, et al:Successful high-dose intravenous immunoglobulin therapy for a patient with fulminant myocarditis. Heart Vessels 22:48-51, 2007.
PubMed
8) Hiramitsu S, Morimoto S, Kato S, et al:Significance of transient left ventricular wall thickening in acute lymphocytic myocarditis. Heart Vessels 22:25-29, 2007.
PubMed
P.188 掲載の参考文献
1) Shiba N, Watanabe J, Shinozaki T, et al:Analysis of chronic heart failure registry in the Tohoku district:Third year follow-up. Circ J 68:427-434, 2004.
PubMed
2) Shiba N, Nochioka K, Miura M, et al:Trend of westernization of etiology and clinical characteristics of heart failure patients in Japan-first report from the CHART-2 study. Circ J 75:823-833, 2011.
PubMed
3) McMurray J, Pfeffer MA:New therapeutic options in congestive heart failure:Part I. Circulation 105:2099-2106, 2002.
PubMed
4) Ponikowsk P, Voors AA, Anker SD, et al:ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37:2129-2200, 2016.
 
5) 日本循環器学会ほか:2020年JCSガイドライン フォーカスアップデート版 冠動脈疾患患者における抗血栓療法. 2020. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/04/JCS2020_Kimura_Nakamura.pdf
 
P.195 掲載の参考文献
1) 日本高血圧学会高血圧治療ガイドライン作成委員会編:高血圧治療ガイドライン2019. 高血圧学会, 東京, 2019.
 
2) 日本高血圧学会編:高血圧診療ステップアップ-高血圧治療ガイドラインを極める. 診療と治療社, 東京, 2019.
 
3) 日本循環器学会/日本心不全学会:急性・慢性心不全診療ガイドライン(2017年改訂版). 2018. https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf
 
4) 甲斐久史:心不全の併存症-病態・治療 高血圧. 日本臨牀77(増2):166-172, 2019.
 
P.208 掲載の参考文献
1) 日本循環器学会/日本心不全学会:心筋症診療ガイドライン(2018年改訂版). 2019. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2018_tsutsui_kitaoka.pdf (2020年10月閲覧)
 
2) Ommen SR, Mital S, Burke MA, et al:2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy:A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 142(25):e558-e631, 2020.
 
3) Elliott PM, Anastasakis A, Borger MA, et al:2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy:the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35:2733-2779, 2014.
 
P.214 掲載の参考文献
1) Maurer MS, Schwartz JH, Gundapaneni B, et al:Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med 379:1007-1016, 2018.
PubMed
2) Adams D, Gonzalez-Duarte A, O'Riordan WD, et al:Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med 379:11-21, 2018.
PubMed
3) Solomon SD, Adams D, Kristen A, et al:Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis. Circulation 139:431-443, 2019.
PubMed
4) Jaccard A, Moreau P, Leblond V, et al:High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med 357:1083-1093, 2007.
PubMed
P.220 掲載の参考文献
1) Desnick RJ, Ioannou YA, Eng CM:α-Galactosidase A deficiency:Fabry disease. The metabolic and molecular basis of inherited disease. 8th ed. McGrawHill, New York, 2001, pp.3733-3774.
 
2) Inoue T, Hattori K, Ihara K, et al:Newborn screening for Fabry disease in Japan:prevalence and genotypes of Fabry disease in a pilot study. J Hum Genet 58:548-552, 2013.
 
3) Kobyashi M, Ohashi T, Iizuka S, et al:Frequency of de novo mutations in Japanese patients with Fabry disease. Mol Genet Metab Rep 1:283-287, 2014.
 
4) 日本先天代謝異常学会編:ファブリー病診療ガイドライン2020. 診断と治療社, 東京, 2020.
 
P.226 掲載の参考文献
1) 日本循環器学会/日本胸部外科学会/日本血管外科学会/日本心臓血管外科学会:2020年改訂版弁膜症治療のガイドライン. 2020. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/04/JCS2020_Izumi_Eishi.pdf
 
2) Elder DH, Wei L, Szwejkowski BR, et al:The impact of renin-angiotensin-aldosterone system blockade on heart failure outcomes and mortality in patients identified to have aortic regurgitation:a large population cohort study. J Am Coll Cardiol 58:2084-2091, 2011.
PubMed
3) Zendaoui A, Lachance D, Roussel E, et al:Usefulness of carvedilol in the treatment of chronic aortic valve regurgitation. Circ Heart Fail 4:207-213, 2011.
PubMed
4) Stone GW, Lindenfeld J, Abraham WT, et al:COAPT Investigators. Transcatheter Mitral-Valve Repair in Patients with Heart Failure. N Engl J Med 379:2307-2318, 2018.
PubMed
P.232 掲載の参考文献
1) 日本循環器学会/日本不整脈心電学会:2020年改訂版 不整脈薬物治療ガイドライン. 2020. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/01/JCS2020_Ono.pdf
 
2) Roy D, Talajic M, Nattel S, et al:Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 358:2667-2677, 2008.
PubMed
3) Hindricks G, Potpara T, Dagres N, et al:2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 42:373-498, 2021.
 
4) Marrouche NF, Brachmann J, Andresen D, et al:Catheter Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med 378:417-427, 2018.
PubMed
5) 日本循環器学会/日本不整脈心電学会:不整脈非薬物治療ガイドライン(2018年改訂版). 2019. https://www.j-circ.or.jp/cms/wp-content/uploads/2018/07/JCS2018_kurita_nogami.pd
 
P.236 掲載の参考文献
1) Kozu K, Sugimura K, Ito M, et al:Current status of long-term prognosis among all subtypes of pulmonary hypertension in Japan. Int J Cardiol 300:228-235, 2020.
PubMed
2) Tatebe S, Fukumoto Y, Sugimura K, et al:Clinical significance of reactive post-capillary pulmonary hypertension in patients with left heart disease. Circ J 76(5):1235-1244, 2012.
PubMed
3) 日本循環器学会ほか:2016年版心臓移植に関する提言 Statement forheart transplantation(JCS2016). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2016_isobe_d.pdf
 
4) Fukuda K, Date H, Doi S, et al:Guidelines for the Treatment of Pulmonary Hypertension (JCS2017/JPCPHS2017). Circ J 83:842-945, 2019.
PubMed
5) Vachiery JL, Tedford RJ, Rosenkranz S, et al:Pulmonary hypertension due to left heart disease. Euro Respir J 53:1801897, 2019.
 
6) Guazzi M, Arena R:Pulmonary hypertension with left-sided heart disease. Nature Reviews Cardiology 7:648-659, 2010.
PubMed
7) Delgado JF, Conde E, Sanchez V, et al:Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. Eur Journal Heart Fail 7:1011-1016, 2005.
PubMed
8) Mudge GH, Goldstein S, Addonizio LJ, et al:24th Bethesda conference:Cardiac transplantation. Task Force 3:Recipient guidelines/prioritization. J Am Coll Cardiol 22:21-31, 1993.
PubMed
P.242 掲載の参考文献
1) 日本循環器学会ほか:成人先天性心疾患診療ガイドライン(2017年改訂版). 2018. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2017_ichida_h.pdf
 
2) Stout KK, Daniels CJ, Aboulhosn JA, et al:2018 AHA/ACC Guideline for the Management of Adults With Congenital Heart Disease:Executive Summary:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 139:e637-e697, 2019.
 
3) Baumgartner H, De Backer J, Babu-Narayan SV, et al:2020 ESC Guidelines for the management of adult congenital heart disease. Eur Heart J 42(6):563-645, 2021.
PubMed
P.248 掲載の参考文献
1) Leya FS, Arab D, Joyal D, et al:The efficacy of brain natriuretic peptide levels in differentiating constrictive pericarditis from restrictive cardiomyopathy. J Am Coll Cardiol 45:1900-1902, 2005.
PubMed
2) Syed FF, Schaff HV, Oh JK:Constrictive pericarditis-a curable diastolic heart failure. Nat Rev Cardiol 11:530-544, 2014.
PubMed
3) Adler Y, Philippe Charron P, Imazio M, et al:2015 ESC Guidelines for the diagnosis and management of pericardial diseases:The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC) Endorsed by:The European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 36:2921-2964, 2015.
 
4) George TJ, Arnaoutakis GJ, Beaty CA, et al:Contemporary etiologies, risk factors, and outcomes after pericardiectomy. Ann Thorac Surg 94:445-451, 2012.
PubMed
5) Steffel J, Verhamme P, Potpara TS, et al:The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 39:1330-1393, 2018.
PubMed
P.255 掲載の参考文献
1) Nichols GA, Gullion CM, Koro CE, et al:The incidence of congestive heart failure in type 2 diabetes. Diabetes Care 27:1879-1884, 2004.
PubMed
2) Zelniler TA, Wiviott SD, Raz I, et al:SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes:a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393:31-39, 2019.
 
3) 日本循環器学会/日本心不全学会:急性・慢性心不全診療ガイドライン(2017年改訂版). 2018. https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf
 
4) Cosentino F, Grant PJ, Aboyans V, et al:2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 41:255-323, 2020.
PubMed
5) Udell JA, Cavender MA, Bhatt DL, et al:Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes:a meta-analysis of randomized controlled trials. Lancet Diabetes Endocrinol 3:356-366, 2015.
 
P.262 掲載の参考文献
1) 日本循環器学会ほか:脳血管障害, 慢性腎臓病, 末梢血管障害を合併した心疾患の管理に関するガイドライン(2014年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2014_itos_h.pdf
 
2) 日本腎臓学会編:エビデンスに基づくCKD診療ガイドライン2018. 東京医学社, 東京, 2018.
 
3) Solomon SD, Rice MM, Jablonski KA, et al:Prevention of Events with ACE inhibition (PEACE) Investigators. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation 114:26-31, 2006.
 
4) Sato T, Yamauchi H, Suzuki S, et al:Distinct prognostic factors in patients with chronic heart failure and chronic kidney disease. Int Heart J 54:311-317, 2013.
PubMed
P.268 掲載の参考文献
1) 日本痛風・核酸代謝学会ガイドライン改訂委員会:高尿酸血症・痛風の治療ガイドライン(第3版). 診断と治療社, 東京, 2018.
 
2) White WB, Saag KG, Becker MA, et al:Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med 378:1200-1210, 2018.
 
3) Johnson TA, Kamatani N, Kuwabara M:Xanthine Oxidase Inhibitor Withdrawal Syndrome? Comment on the Article by Choi et al. Arthritis Rheumatol 71:1966-1967, 2019.
 
4) Mackenzie IS, Ford I, Nuki G, et al:Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST):a multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet 396:1745-1757, 2020.
 
P.275 掲載の参考文献
1) Chen W, Thomas J, Sadatsafavi M, FitzGerald JM:Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease:a systematic review and meta-analysis. Lancet Respir Med 3:631-639, 2015
PubMed
2) 日本循環器学会/日本心不全学会:慢性・急性心不全診療ガイドライン(2017年改訂版). 2018. https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf
 
3) 日本呼吸器学会COPDガイドライン第5版作成委員会編:COPD(慢性閉塞性肺疾患)診断と治療のためのガイドライン2018. 2018.
 
4) 大西勝也:新しいLABAオンブレスによるCOPD治療のパラダイムシフト. IV 循環器専門医からみたオンブレスの有用性. 吸入療法 4:46-52, 2012.
 
5) Onishi K, Yoshimoto D, Hagan GW, Jones PW:Prevalence of airflow limitation in outpatients with cardiovascular diseases in Japan. Int J Chron Obstruct Pulmon Dis 9:563-568, 2014.
PubMed
6) Nishimura K, Nishimura T, Onishi K, et al:Changes in plasma levels of B-type natriuretic peptide with acute exacerbations of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 9:155-162, 2014.
PubMed
7) Onishi K:Total management of chronic obstructive pulmonary disease (COPD) as an independent risk factor for cardiovascular disease. J Cardiol 70:128-134, 2017.
PubMed
P.281 掲載の参考文献
1) Yamauchi T, Sakata Y, Takada T, et al:Prognostic Impact of Anemia in Patients With Chronic Heart Failure-With Special Reference to Clinical Background:Report From the CHART-2 Study. Circ J 79:1984-1993, 2015.
PubMed
2) Klip IT, Comin-Colet J, Voors AA, et al:Iron deficiency in chronic heart failure:an international pooled analysis. Am Heart J 165:575-582, e3, 2013.
 
3) Beverborg NG, van der Wal HH, Klip IT, et al:High serum erythropoietin levels are related to heart failure development in subjects from the general population with albuminuria:data from PREVEND. Eur J Heart Fail 18:814-821, 2016.
 
4) Kajimoto K, Sato N, Takano T:Association between anemia, clinical features and outcome in patients hospitalized for acute heart failure syndromes. Eur Heart J Acute Cardiovasc Care 4:568-576, 2015.
PubMed
5) 日本循環器学会/日本心不全学会:急性・慢性心不全診療ガイドライン(2017年改訂版). 2018. https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf
 
6) Yancy CW, Jessup M, Bozkurt B, et al:2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 136:e137-e161, 2017.
 
7) Beverborg GN, van Veldhuisen DJ, van der Meer P:Anemia in Heart Failure:Still Relevant? JACC Heart Fail 6:201-208, 2018.
 
8) Naito Y, Hirotani S, Sawada H, et al:Dietary iron restriction prevents hypertensive cardiovascular remodeling in Dahl salt-sensitive rats. Hypertension 57:497-504, 2011.
PubMed
9) Swedberg K, Young JB, Anand IS, et al:Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl Med 368:1210-1219, 2013.
PubMed
10) van der Meer P, Voors AA, Lipsic E, et al:Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure. J Am Coll of Cardiol 44:63-67, 2004.
PubMed
P.293 掲載の参考文献
1) Verbrugge FH, Steels P, Grieten L, et al:Hyponatremia in acute decompensated heart failure:depletion versus dilution. J Am Coll Cardiol 65:480-492, 2015.
PubMed
2) Konstam MA, Gheorghiade M, Burnett JC Jr, et al:Effects of oral tolvaptan in patients hospitalized for worsening heart failure:the EVEREST Outcome Trial. JAMA 297:1319-1331, 2007.
PubMed
3) Licata G, Di Pasquale P, Parrinello G, et al:Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure:long-term effects. Am Heart J 145:459-466, 2003.
PubMed
4) Felker GM, Lee KL, Bull DA, et al:Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 364:797-805, 2011.
PubMed
5) Goyal A, Spertus JA, Gosch K, et al:Serum potassium levels and mortality in acute myocardial infarction. JAMA 307:157-164, 2012.
PubMed
6) Franse LV, Pahor M, Di Bari M, et al:Hypokalemia Associated With Diuretic Use and Cardiovascular Events in the Systolic Hypertension in the Elderly Program. Hypertension 35:1025-1030, 2000.
PubMed
7) Pitt B, Zannad F, Remme WJ, et al:The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709-717, 1999.
 
8) Juurlink DN, Mamdani MM, Lee DS, et al:Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351:543-551, 2004.
PubMed
9) Allon M:Hyperkalemia in end-stage renal disease:mechanisms and management. J Am Soc Nephrol 6(4):1134-1142, 1995.
PubMed

書評

最近チェックした商品履歴

Loading...